comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 09:21:23 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： FDA scientists endorse Pfizer/BioNTech Covid

focus

WSS

How to ethically and practically extend health care to all

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Chimpanzees, like humans and whales, get menopause: Study

Group behind ProMed defends move to subscription

Alnylam reports growth in sales of rare disease treatments

How I helped Pfizer think through the ethics of Viagra

leisure time

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Physician subsidies by hospitals soar in wake of No Surprises Act

Wildfire smoke exposes gaps in outdoor worker protections

The a glaring gap in research on serious mental illness and primary care

New air purifier tech could be key to improving indoor air quality

Cassava reveals details — and problems — with Alzheimer's study

Continuity nursing helped my family in our darkest PICU moments

Why Sanofi got shellacked over its spinoff

Wildfire smoke exposes gaps in outdoor worker protections

Group behind ProMed defends move to subscription

Wikipedia

The pink breast cancer awareness ribbon needs a redesign

The pink breast cancer awareness ribbon needs a redesign

Traditional Chinese medicine benefits explored in new JAMA study

Meta's Zuckerberg and Chan on track to put $50 billion into science

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

leisure time

knowledge

focus

leisure time